Antithymocyte globulin combined with cyclosporine A down-regulates T helper 1 cells by modulating T cell immune response cDNA 7 in aplastic anemia
- 220 Downloads
Antithymocyte globulin (ATG) combined with cyclosporine A (CsA) has been widely used as a standard regimen in the treatment of aplastic anemia (AA), especially in severe aplastic anemia (SAA). Abnormally activated T cells might be the immune pathogenesis of AA. T cell immune response cDNA 7 (TIRC7) has been demonstrated its essential role in T cell activation; however, little is known about the role of TIRC7 in AA. In this study, we documented that TIRC7 levels in CsA group were higher than that in ATG + CsA (AC) group only in the follow-up phase (P < 0.05; P < 0.05); nevertheless, TIRC7 levels in SAA group were elevated than non severe aplastic anemia group not only in the treatment phase (P < 0.05; P < 0.05) but also in the follow-up phase (P < 0.05; P < 0.01). The trend of changes of T helper (Th) 1, Th17 and Th22 levels before and after treatment was similar to the changes of TIRC7 levels in either AC group or CsA group. Thus, TIRC7 might be involved in the pathogenesis of AA and AC might down-regulate Th1 cells by modulating the expression of TIRC7 in AA.
KeywordsAntithymocyte globulin Aplastic anemia Cyclosporine A T cell immune response cDNA 7 T helper 1 (IFN-γ)
We would like to thank all patients for their collaboration. We also thank Xiu-ying Pan, Xu-peng He, Hai-ying Sun, De-peng Li, Yi-hong Huang, Zhi-ling Yan, Wei Sang and Jiang Cao for their clinical assistance to patients included in this study. This work was supported by grants from the National Nature Science Foundation of China (Grant Nos. 81270637, 81300441).
Conflict of interest
The authors have no conflicts of interest to declare.
- 5.Chatterjee S, Dutta RK, Basak P, Das P, Das M, Pereira JA, et al. Alteration in marrow stromal microenvironment and apoptosis mechanisms involved in aplastic anemia: an animal model to study the possible disease pathology. Stem Cells Int. 2010;2010:932354. doi: 10.4061/2010/932354.PubMedCentralPubMedGoogle Scholar
- 20.Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA working party of the European Group for blood and marrow transplantation. Blood. 2011;117(17):4434–41. doi: 10.1182/blood-2010-08-304071.PubMedCrossRefGoogle Scholar
- 23.Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European blood and marrow transplant (EBMT) severe aplastic anaemia working party. Blood. 1999;93(7):2191–5.PubMedGoogle Scholar